FDA issues Complete Response Letter rejecting Summit’s ivonescimab lung‑cancer application

Summit Therapeutics announced that the U.S. Food and Drug Administration issued a Complete Response Letter for the Biologics License Application of ivonescimab in EGFR‑mutated non‑small cell lung cancer. The agency said the data did not show a statistically significant overall‑survival benefit, even though the Phase III HARMONi trial met its progression‑free survival endpoint. Summit said it will continue development and discuss next steps with the FDA.

The rejection halts any immediate U.S. launch of ivonescimab, removing a near‑term revenue source and adding regulatory uncertainty for the company (the company’s statement says it will continue development). Analysts noted the decision was largely anticipated, but it still drove a sharp share‑price decline (the stock fell about 20% in pre‑market trading).

  • 1The FDA issued a Complete Response Letter on November 15, 2026 for Summit’s BLA for ivonescimab plus chemotherapy in locally advanced or metastatic NSCLC.
  • 2The agency cited insufficient evidence of a statistically significant overall‑survival (OS) improvement as the reason for the CRL.
  • 3The HARMONi Phase III trial met its primary progression‑free survival (PFS) endpoint, showing a 43% reduction in risk of disease progression or death versus chemotherapy alone.
  • 4In a post‑hoc analysis, the trial reported an overall‑survival hazard ratio of 0.76 across the full population, but the result was not statistically significant.
  • 5Summit’s shares fell roughly 20% in pre‑market trading after the announcement.
  • 6Summit said it will continue developing ivonescimab in other indications and discuss next steps with the FDA.

Sources